Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
US Army
Johnson and Johnson
Fish and Richardson
QuintilesIMS
Fuji
Healthtrust
Cantor Fitzgerald

Generated: June 22, 2018

DrugPatentWatch Database Preview

ALPHAGAN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Alphagan patents expire, and when can generic versions of Alphagan launch?

Alphagan is a drug marketed by Allergan and is included in four NDAs. There are seven patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Drug patent expirations by year for ALPHAGAN
Medical Subject Heading (MeSH) Categories for ALPHAGAN
Synonyms for ALPHAGAN
(4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate
(5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate
109826-56-4
1400635-36-0
359B465
4S9CL2DY2H
5-bromo-6-(2-imidazolidinylideneamino) quinoxaline l-tartrate
5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline tartrate
5-bromo-N-
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-Tartrate
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine tartrate
5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)-6-Quinoxalinamine TaTRate
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; (2R,3R)-2,3-dihydroxybutanedioic acid
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; (2S,3S)-2,3-dihydroxybutanedioic acid
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine(2R,3R)-2,3-dihydroxysuccinate
59803-98-4 (Parent)
59803-99-5
6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
70359-46-5
79570-19-7
A19740
AB0021226
AC-3599
AC1L1GYC
AC1OCEPC
AC1Q59OR
ACT08633
AGN 190342-LF
AGN 190342LF
AGN-190342-LF
Aiphagan
Aiphagan P
AK-68418
AK142929
AKOS015895446
AKOS016845265
AKOS022175702
Alphagan (TN)
Alphagan Z
AN-12800
API0007067
API0007142
AS-12798
AS-18083
AX8282531
BC004062
BC208828
Brimonidine D-tartarate
Brimonidine D-tartrate
Brimonidine L-tartarate
Brimonidine L-Tartrate
brimonidine Purite
Brimonidine tartarate
BRIMONIDINE TARTRATE
brimonidine tartrate (1:1), (S-(R*,R*))-isomer
Brimonidine tartrate (JAN/USAN)
Brimonidine tartrate [USAN:JAN]
Brimonidine tartrate [USAN]
Brimonidine tartrateUK 14,304 tartrate
Brimonidinne tartrate
Brominide tartrate
C11H10BrN5.C4H6O6
C15H16BrN5O6
CCG-221278
CHEMBL2062257
CS-4496
CTK3J3327
D00ARM
D02076
DR002734
DTXSID20426066
EBD23481
FT-0082637
HMS3652B06
HY-B0659A
I06-0561
KB-42499
KS-00000K6V
KSC493G2P
L(+)-TARTARIC ACID; BRIMONIDINE
LS-177484
LS40084
MFCD07773072
MolPort-003-845-306
MolPort-016-638-379
MolPort-023-220-671
MolPort-035-395-833
N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2R,3R)-2,3-dihydroxybutanedioic acid
Novadur
PubChem15967
Qoliana
RT-001413
S-8158
S4266
SCHEMBL265607
SCHEMBL34647
SCHEMBL34649
SNJ-2022
ST24046243
ST51052789
TL8006987
UK 14,304 (tartrate)
UK 14,304 tartrate
UK-14304-18
UK-1430418
UK14,304TARTRATE
UNII-4S9CL2DY2H
VA10431
W0014

US Patents and Regulatory Information for ALPHAGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan ALPHAGAN brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 020613-001 Sep 6, 1996 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021262-001 Mar 16, 2001 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ALPHAGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan ALPHAGAN brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 020613-001 Sep 6, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan ALPHAGAN brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 020613-001 Sep 6, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan ALPHAGAN brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 020613-001 Sep 6, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALPHAGAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Deloitte
Chubb
Farmers Insurance
Citi
Dow
Fish and Richardson
Cipla
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.